March 30, 2026
Post-ELCC 2026: Panelists discuss clinical decision-making in EGFR-mutated non-small cell lung cancer, focusing on how emerging data are shaping treatment selection, risk–benefit assessment, and sequencing across lines of therapy, including monotherapy versus combination strategies, key efficacy and safety considerations, biomarker testing such as MET alterations, the emerging role of TROP2-directed antibody–drug conjugates, and the impact of subcutaneous administration on treatment burden and patient experience, with the goal of providing practical, evidence-informed insights to support clinical decision-making.
Related Posts
EGFR-Mutated NSCLC: Interpreting Efficacy Outcomes in First-Line Therapy
EGFR-Mutated NSCLC: Risk–Benefit Assessment in First-Line Treatment Decisions
EGFR-Mutated NSCLC: Impact of Subcutaneous Administration on Treatment Experience
EGFR-Mutated NSCLC: Integrating Emerging ELCC Data Into Treatment Sequencing
EGFR-Mutated NSCLC: Emerging Role of TROP2-Directed Antibody–Drug Conjugates
EGFR-Mutated NSCLC: Role of Value-Based Frameworks in Treatment Evaluation
EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved Case
EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination Therapy
